We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2012 by Institute of Liver and Biliary Sciences, India.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01676597
First Posted: August 31, 2012
Last Update Posted: December 17, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Institute of Liver and Biliary Sciences, India
  Purpose
  • The study will be a prospective open labelled double blinded randomized controlled study.
  • The study will be conducted on patients admitted to Department of Hepatology from 2012 to 2014 at Institute of Liver and Biliary Sciences, New Delhi
  • Patients diagnosed as having clinical or subclinical hepatopulmonary syndrome will be started on oral pentoxifylline therapy 400 mg thrice daily for 12 weeks.
  • Patients not responding to this therapy will be given divided into 2 arms with one arm receiving additional Tab Rifaximin 400 mg thrice daily or placebo for 12 weeks.

Condition Intervention
Hepatopulmonary Syndrome Drug: pentoxifylline and rifaximin Drug: Pentoxifylline and placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Institute of Liver and Biliary Sciences, India:

Primary Outcome Measures:
  • Complete response after 3 months of treatment [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Development of serious adverse effects leading to withdrawal of the drug [ Time Frame: 3 months ]

Estimated Enrollment: 80
Study Start Date: September 2012
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rifaximin and pentoxifylline
Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
Drug: Pentoxifylline and placebo
Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
Active Comparator: pentoxifylline and placebo
Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
Drug: pentoxifylline and rifaximin
Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Evidence of portal hypertension (esophagogastric varices or portal hypertensive gastropathy identified on esophagogastroduodenoscopy, and/or varices seen on computerized tomography scan or ultrasound, and/or splenomegaly with no other explanation, and/or ascites with no other explanation)
  2. Intrapulmonary vascular dilatations (IPVDs) diagnosed on contrast echocardiogram (CE)
  3. AaDO2 > 15 mm Hg on standing room air arterial blood gas (ABG)
  4. Ability and willingness to give informed consent

Exclusion Criteria:

  • Age < 18 or > 64
  • Intrinsic significant cardiopulmonary disease
  • Inability to perform pulmonary function tests
  • Moderate to severe Pulmonary hypertension
  • Advanced hepatic encephalopathy
  • Inadequate echocardiographic window to allow for accurate transthoracic contrast echocardiography
  • Antibiotic use within the last one month
  • Listed for liver transplant in next 4 weeks
  • Current use of exogenous nitrates
  • Active bacterial infections
  • Known malignancy
  • Known intolerance to Pentoxifylline or rifaximin
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01676597


Contacts
Contact: Dr Naveen Kumar, MD 011-46300000 naveenilbsdelhi@gmail.com
Contact: Dr Ankit Bhardwaj 011-46300000 ext 1032 bhardwaj.ankit3@gmail.com

Locations
India
Institute of Liver and Biliary Sciences Recruiting
New Delhi, Delhi, India, 110070
Contact: Dr Naveen , MD    011-46300000    naveenilbsdelhi@gmail.com   
Contact: Dr Ankit Bhardwaj    011-46300000 ext 1032    bhardwaj.ankit3@gmail.com   
Sponsors and Collaborators
Institute of Liver and Biliary Sciences, India
Investigators
Principal Investigator: Dr Naveen Kumar, MD Institute of Liver and Biliary Sciences
  More Information

Responsible Party: Institute of Liver and Biliary Sciences, India
ClinicalTrials.gov Identifier: NCT01676597     History of Changes
Other Study ID Numbers: ILBS-HPS-01
First Submitted: August 29, 2012
First Posted: August 31, 2012
Last Update Posted: December 17, 2013
Last Verified: December 2012

Additional relevant MeSH terms:
Syndrome
Hepatopulmonary Syndrome
Disease
Pathologic Processes
Liver Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Rifaximin
Rifamycins
Pentoxifylline
Anti-Infective Agents
Gastrointestinal Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Phosphodiesterase Inhibitors
Platelet Aggregation Inhibitors
Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs
Vasodilator Agents
Free Radical Scavengers
Antioxidants